Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/how-trump-s-tariffs-on-imported-drugs-can-hurt-supply-chains-consumers-and-industry
16 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/16/2964011/0/en/Calliditas-Therapeutics-to-Present-Four-Abstracts-at-American-Society-of-Nephrology-ASN-Kidney-Week-2024.html
16 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/delisting-of-calliditas-therapeutics-ab-publ-from-nasdaq-stockholm-302249090.html
03 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/calliditas-therapeutics-takes-certain-corporate-actions-following-announcement-by-asahi-kasei-302236575.html
03 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/notice-of-extraordinary-meeting-of-calliditas-therapeutics-ab-publ-302236607.html
12 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/calliditas-interim-report-january-to-june-2024-302220670.html
05 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/invitation-to-the-presentation-of-calliditass-interim-report-january--june-2024-302214090.html
Details:
Nefecon (budesonide) is a patented, oral delayed-release corticosteroid approved for primary IgA nephropathy treatment.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Everest Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2024
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Everest Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Announces Seven-Year Orphan Drug Exclusivity for Nefecon®
Details : Nefecon (budesonide) is a patented, oral delayed-release corticosteroid approved for primary IgA nephropathy treatment.
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
November 03, 2024
Details:
GKT 831 (setanaxib) is a first‐in‐class selective NOX 1/4 inhibitor. It is being evaluated for the treatment of patients with primary biliary cholangitis
Lead Product(s): Setanaxib
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: GKT137831
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 26, 2024
Lead Product(s) : Setanaxib
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Announces Positive TRANSFORM Phase 2b Data in Primary Biliary Cholangitis
Details : GKT 831 (setanaxib) is a first‐in‐class selective NOX 1/4 inhibitor. It is being evaluated for the treatment of patients with primary biliary cholangitis
Product Name : GKT137831
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 26, 2024
Details:
GKT 831 (setanaxib) is a first‐in‐class selective NOX 1/4 inhibitor. It is being evaluated for the treatment of patients with squamous cell carcinoma of the head and neck.
Lead Product(s): Setanaxib,Pembrolizumab
Therapeutic Area: Oncology Brand Name: GKT137831
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 05, 2024
Lead Product(s) : Setanaxib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Reports Positive Phase 2 Results for Head and Neck Cancer Trial with Setanaxib
Details : GKT 831 (setanaxib) is a first‐in‐class selective NOX 1/4 inhibitor. It is being evaluated for the treatment of patients with squamous cell carcinoma of the head and neck.
Product Name : GKT137831
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2024
Details:
TARPEYO (budesonide) is an oral, delayed-release formulation for primary IgA nephropathy, utilizing a corticosteroid with potent glucocorticoid activity.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 03, 2024
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO®
Details : TARPEYO (budesonide) is an oral, delayed-release formulation for primary IgA nephropathy, utilizing a corticosteroid with potent glucocorticoid activity.
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
June 03, 2024
Details:
Kinpeygo (budesonide), a modified-release capsule, Glucocorticoid receptor agonist, has been approved for primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 30, 2024
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas's STADA Receives Positive CHMP Opinion for Kinpeygo® in IgA Nephropathy
Details : Kinpeygo (budesonide), a modified-release capsule, Glucocorticoid receptor agonist, has been approved for primary IgA nephropathy.
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
May 30, 2024
Details:
Nefecon is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, indicated for IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2024
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
Details : Nefecon is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity, indicated for IgA nephropathy.
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
May 14, 2024
Details:
Tarpeyo (Budesonide), a delayed-release capsule and a Glucocorticoid receptor agonist, has been approved by the U.S. FDA for the indication of kidney function loss in adults with primary IgA nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2023
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Therapeutics Announces Full FDA Approval of TARPEYO®, the Only FDA-approved Treatment ...
Details : Tarpeyo (Budesonide), a delayed-release capsule and a Glucocorticoid receptor agonist, has been approved by the U.S. FDA for the indication of kidney function loss in adults with primary IgA nephropathy.
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
December 20, 2023
Details:
Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary iga nephropathy.
Lead Product(s): Budesonide
Therapeutic Area: Nephrology Brand Name: Nefecon
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2023
Lead Product(s) : Budesonide
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nefecon is a patented oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. It is being investigated for primary iga nep...
Product Name : Nefecon
Product Type : Steroid
Upfront Cash : Inapplicable
December 03, 2023
Details:
GKT137831 (setanaxib) is a small molecule oral inhibitor which works by targeting NOX 1/NOX 4, it is currently being investigated for the treatment of Alport syndrome.
Lead Product(s): Setanaxib
Therapeutic Area: Genetic Disease Brand Name: GKT137831
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2023
Lead Product(s) : Setanaxib
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Calliditas Initiates Clinical Study to Evaluate Setanaxib in Alport Syndrome
Details : GKT137831 (setanaxib) is a small molecule oral inhibitor which works by targeting NOX 1/NOX 4, it is currently being investigated for the treatment of Alport syndrome.
Product Name : GKT137831
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2023
Details:
GKT137831 (setanaxib), an oral tablet, is a NOX 1 and 4 inhibitor, which is being investigated for the treatment of Alport syndrome and orphan drug designation by the FDA.
Lead Product(s): Setanaxib
Therapeutic Area: Genetic Disease Brand Name: GKT137831
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 27, 2023
Lead Product(s) : Setanaxib
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GKT137831 (setanaxib), an oral tablet, is a NOX 1 and 4 inhibitor, which is being investigated for the treatment of Alport syndrome and orphan drug designation by the FDA.
Product Name : GKT137831
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2023
ABOUT THIS PAGE